Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for REGENXBIO Inc. (RGNX : NSDQ)

• Company Description    REGENXBIO Inc. is a biotechnology company. The Company focuses on the development, commercialization and licensing of recombinant adeno-associated virus gene therapy. Its products candidates include RGX-501, for the treatment of homozygous familial hypercholesterolemia which uses the AAV8 vector to deliver the human low-density lipoprotein receptor gene to liver cells; RGX-111, for the treatment of Mucopolysaccharidosis Type I which uses the AAV9 vector to deliver the human a-l-iduronidase gene to the central nervous system; RGX-121, for the treatment of Mucopolysaccharidosis Type II; RGX-314, for the treatment of wet age-related macular degeneration and RGX-321, for the treatment of X-linked retinitis pigmentosa. REGENXBIO Inc. is headquartered in Rockville, Maryland. Number of Employees: 371

• Price / Volume Information    Yesterday's Closing Price: $6.35 Daily Weekly Monthly 20 Day Moving Average: 1,891,935 shares Shares Outstanding: 51.70 (millions) Market Capitalization: $328.28 (millions) Beta: 1.12 52 Week High: $16.19 52 Week Low: $5.46 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -29.37% -32.82% 12 Week -27.43% -32.91% Year To Date -55.90% -56.90%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 9804 MEDICAL CENTER DRIVE - ROCKVILLE,MD 20850 USA ph: 240-552-8181 fax: - ir@regenxbio.com http://www.regenxbio.com

• General Corporate Information    Officers Curran Simpson - Chief Executive Officer; President and Director Kenneth T. Mills - Chairman of the Board of Directors Mitchell Chan - Chief Financial Officer Jean Bennett - Director Allan M. Fox - Director Peer Information REGENXBIO Inc. (CORR.) REGENXBIO Inc. (RSPI) REGENXBIO Inc. (CGXP) REGENXBIO Inc. (BGEN) REGENXBIO Inc. (GTBP) REGENXBIO Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 75901B107 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/06/26 Share - Related Items Shares Outstanding: 51.70 Most Recent Split Date: (:1) Beta: 1.12 Market Capitalization: $328.28 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $0.17 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-3.32 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 37.53% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/06/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 15.57 Price/Cash Flow: - Price / Sales: 3.74 EPS Growth vs. Year Ago Period: -1,533.33% vs. Previous Quarter: -32.31% Sales Growth vs. Year Ago Period: -92.82% vs. Previous Quarter: -78.93% ROE 03/31/26 - -232.50 12/31/25 - -103.12 09/30/25 - -78.29 ROA 03/31/26 - -61.02 12/31/25 - -37.83 09/30/25 - -34.49 Current Ratio 03/31/26 - 2.62 12/31/25 - 2.38 09/30/25 - 2.66 Quick Ratio 03/31/26 - 2.62 12/31/25 - 2.38 09/30/25 - 2.66 Operating Margin 03/31/26 - -330.23 12/31/25 - -113.75 09/30/25 - -110.29 Net Margin 03/31/26 - -330.23 12/31/25 - -113.75 09/30/25 - -110.29 Pre-Tax Margin 03/31/26 - -330.23 12/31/25 - -113.75 09/30/25 - -110.29 Book Value 03/31/26 - 0.41 12/31/25 - 2.03 09/30/25 - 3.20 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00 Debt-to-Capital 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00

Powered by Zacks Investment Research ©